(From July 2007 MedMarkets.)
In July, it was reported by Johnson & Johnson that the company’s second quarter U.S. sales of Cypher, its landmark drug-eluting stent, were off 41% from 2006, while non-U.S. sales had fallen by a less precipitous 30%. Three facts were eminently behind this decline: the late-stage thrombosis problem linked to drug-eluting stents, the irrepressible [...]
bookmark to
